BRCA1 and neoplasm: Furthermore, the development of resistance to cisplatin or PARPi involves restoration of BRCA1/2 function, achieved either by the second mutation in the affected copy of the gene or selection of pre-existing BRCA1-proficient tumor cells (Lord and Ashworth, 2013; Sokolenko et al., 2017).